New model of oropharyngeal candidiasis in mice

被引：85

作者：

Kamai, Y

Kubota, M

Kamai, Y

Hosokawa, T

Fukuoka, T

Filler, SG

机构：

[1] Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan

[2] Sankyo Co Ltd, Lab Anim Sci & Toxicol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan

[3] Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 11期

关键词：

D O I：

10.1128/AAC.45.11.3195-3197.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We established a straightforward murine model of oropharyngeal candidiasis. Mice were immunosuppressed with cortisone acetate, anesthetized, and then inoculated by placing cotton wool balls saturated with Candida albicans sublingually for 2 h. A prolonged, reproducible infection was induced. This model may be useful for antifungal screening or pathogenesis studies.

引用

收藏

页码：3195 / 3197

页数：3

相关论文

共 10 条

[1] New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4(+) T-cell-deficient mice for evaluation of antifungal agents [J].

Flattery, AM ;

Abruzzo, GK ;

Gill, CJ ;

Smith, JG ;

Bartizal, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) :1604-1609

[2] ISOLATION OF THE CANDIDA-ALBICANS GENE FOR OROTIDINE-5'-PHOSPHATE DECARBOXYLASE BY COMPLEMENTATION OF S-CEREVISIAE URA3 AND ESCHERICHIA-COLI PYRF MUTATIONS [J].

GILLUM, AM ;

TSAY, EYH ;

KIRSCH, DR .

MOLECULAR & GENERAL GENETICS, 1984, 198 (01) :179-182

[3] ORAL CANDIDIASIS IN HIGH-RISK PATIENTS AS THE INITIAL MANIFESTATION OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].

KLEIN, RS ;

HARRIS, CA ;

SMALL, CB ;

MOLL, B ;

LESSER, M ;

FRIEDLAND, GH .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (06) :354-358

[4] Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats [J].

Martinez, A ;

Regadera, J ;

Jimenez, E ;

Santos, I ;

Gargallo-Viola, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1008-1013

[5]

National Committee for Clinical Laboratory Standards, 1997, REF METH BROTH DIL A

[6] Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis [J].

Petraitis, V ;

Petraitiene, R ;

Groll, AH ;

Sein, T ;

Schaufele, RL ;

Lyman, CA ;

Francesconi, A ;

Bacher, J ;

Piscitelli, SC ;

Walsh, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :471-479

[7] ORAL CANDIDIASIS AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].

SAMARANAYAKE, LP ;

HOLMSTRUP, P .

JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1989, 18 (10) :554-564

[8] Experimental oral candidiasis in animal models [J].

Samaranayake, YH ;

Samaranayake, LP .

CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (02) :398-+

[9] EPIDEMIOLOGY OF ORAL CANDIDIASIS IN HIV-INFECTED PATIENTS - COLONIZATION, INFECTION, TREATMENT, AND EMERGENCE OF FLUCONAZOLE RESISTANCE [J].

SANGEORZAN, JA ;

BRADLEY, SF ;

HE, XG ;

ZARINS, LT ;

RIDENOUR, GL ;

TIBALLI, RN ;

KAUFFMAN, CA .

AMERICAN JOURNAL OF MEDICINE, 1994, 97 (04) :339-346

[10]

Walsh TJ, 2000, J CLIN MICROBIOL, V38, P2369